Viridian Therapeutics, Inc. (VRDN) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2025. Viridian Therapeutics is a biopharmaceutical company focused on developing best-in-class medicines for serious and rare diseases, primarily targeting Thyroid Eye Disease (TED) and autoimmune conditions via FcRn inhibitors. The company has no approved products and has not generated revenue from product sales.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Revenue | $75 | $72 | $147 | $144 |
| Net Loss | $(100,735) | $(64,993) | $(187,647) | $(113,535) |
| Net Loss Per Share (Basic/Diluted) | $(1.00) | $(0.77) | $(1.87) | $(1.37) |
| Operating Expenses | $106,842 | $72,259 | $200,780 | $128,227 |
| Cash, Cash Equivalents & Short-Term Investments | $563.4 million (as of June 30, 2025) | |||
| Accumulated Deficit | $1,183.5 million (as of June 30, 2025) |
Material Changes vs. Prior Period
- Revenue: Remained negligible, derived solely from collaboration revenue with Zenas BioPharma ($75k in Q2 2025 vs. $72k in Q2 2024).
- Net Loss: Increased significantly by 55% in Q2 2025 compared to Q2 2024, driven by higher R&D and G&A expenses.
- R&D Expenses: Rose to $86.6 million in Q2 2025 from $56.2 million in Q2 2024. The increase was primarily due to:
- $15.4 million increase in TED portfolio costs (clinical trials and manufacturing for veligrotug and VRDN-003).
- $11.3 million increase in FcRn inhibitor portfolio costs (IND-enabling activities for VRDN-006 and VRDN-008).
- G&A Expenses: Increased to $20.2 million in Q2 2025 from $16.1 million in Q2 2024, driven by market research for commercialization preparation and increased headcount.
- Liquidity: Cash and short-term investments decreased from $714.0 million at year-end 2024 to $563.4 million at June 30, 2025, reflecting operating cash burn of $168.0 million for the six-month period.
Guidance, Outlook, and Risks
- Clinical Milestones:
- Veligrotug (TED): Phase 3 THRIVE and THRIVE-2 trials met primary endpoints. FDA granted Breakthrough Therapy designation in May 2025. Company anticipates submitting a Biologics License Application (BLA) in H2 2025 and an MAA to the EMA in H1 2026.
- VRDN-003 (TED): Phase 3 REVEAL-1 and REVEAL-2 trials are ongoing. Topline data expected H1 2026. BLA submission anticipated by end of 2026.
- VRDN-006 (FcRn): IND cleared in Jan 2025. Proof-of-concept IgG reduction data expected in Q3 2025.
- VRDN-008 (FcRn): IND submission anticipated by end of 2025.
- Capital Resources: Management expects current resources ($563.4 million) to fund operations into the second half of 2027. However, the company will require additional capital to continue development and commercialization.
- Subsequent Event: In July 2025, Viridian entered a collaboration with Kissei Pharmaceutical for veligrotug and VRDN-003 in Japan, receiving a $70 million upfront payment with up to $315 million in potential milestones.
- Risks:
- Regulatory: Potential delays due to FDA workforce reductions or policy changes under the current administration.
- Supply Chain: Reliance on Chinese CDMOs (e.g., WuXi Biologics) exposes the company to geopolitical risks and potential U.S. legislative restrictions (e.g., BIOSECURE Act).
- Financial: Continued operating losses and the need for future equity or debt financing, which may result in dilution.
Investor Verification Checklist
- Verify the impact of the July 2025 Kissei Pharmaceutical agreement on cash flow and future revenue recognition.
- Monitor the timeline for the veligrotug BLA submission (H2 2025) and potential regulatory feedback.
- Assess the company's strategy to mitigate supply chain risks related to Chinese manufacturers (WuXi Biologics) amidst potential U.S. legislative changes.
- Review the burn rate relative to the $563.4 million cash balance to confirm the runway into H2 2027.
- Track the progress of the VRDN-006 proof-of-concept data expected in Q3 2025.